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ABSTRACT 
 
The population of patients who have been diagnosed with diabetes mellitus (Type 1 or 
Type 2) has been increasing in the United States. Patients with type 1 diabetes may receive 
insulin through delivery via insulin pump therapy (IPT) or multiple daily insulin injections 
(MDII). In addition to requiring insulin, other management regimens have included frequent 
blood glucose monitoring, checking laboratory values hemoglobin A1c (A1C), maintaining 
normal body mass index (BMI), keeping a balanced diet, carbohydrate counting, and exercise. 
The purpose of the study was to compare the retrospective data of A1C and BMI of patients with 
type 1 diabetes after they transition from MDII to IPT. 
An investigation was conducted retrospectively using a non-experimental chart review at 
an outpatient endocrinology department in Northern California. Electronic data collection 
technology was utilized to collect information about patient’s age, gender, BMI, and A1C. Data 
of the dependent variables, such as A1C, and BMI, were collected at baseline pre-IPT and 3, 6, 
and 12 months post-IPT.  
Results indicated that the mean A1C decreased significantly from baseline to 3 months 
and 3-6 months post-IPT period. However, there was no difference in mean A1C from baseline 
to 12 months post-IPT. Mean BMI increased significantly from baseline to 3 months post-IPT. 
However, there was no difference in mean BMI from baseline to 3-6 months and baseline to 12 
months post-IPT. This quality improvement research study supports that there was no significant 
decrease in either A1C or BMI after a patient transitions from MDII to IPT within the first 12 
months.  
Sima Sapkota 
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CHAPTER 1: INTRODUCTION 
According to the Centers for Disease Control and Prevention (CDC, 2014) patients with 
diabetes account for approximately 29.1 million people, or 9.3% of the total population. Of 
these, an estimated 8.1 million people remain undiagnosed, which results in delays in treatment, 
increased risk of complications, and increased health care costs. The estimated diabetes mellitus 
(Type 1 or Type 2) related cost in the United States is increasing. In 2012, diabetes related total 
costs were $245 billion (CDC, 2014). Medical related costs comprised $176 billion, and $69 
billion was related to disability, work loss, and premature death of patients. In fact, the CDC 
(2014) estimates that overall medical expenses were 2.3 times more for people with diabetes than 
those without diabetes. 
Despite investment in better diabetes prevention and care, diabetes mellitus is still the 
seventh leading cause of death in the United States (CDC, 2014). A large clinical trial, Diabetes 
Control and Complications Trial (DCCT) conducted over 10-years showed better control of 
diabetes, delayed the progression of micro and macro vascular complications (Nathan et al., 
1993). Clients involved in the clinical trial had delayed disease progression when insulin therapy 
was used to improve glycemic control.  It is therefore vital to improve glycemic control of 
patients with diabetes mellitus to reduce long-term complications and premature death. 
Background and Significance  
Type 1 Diabetes 
Type 1 diabetes is an autoimmune disease which causes destruction of beta cells in the 
pancreas leading to lack of insulin production. Insulin is necessary for the body to maintain 
stable blood glucose levels. Therefore, in type 1 diabetes, exogenous insulin administration is the 
most important part of disease management (American Diabetes Association [ADA], 2016). 
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Exogenous insulin delivery may fall into two different regimens: insulin pump therapy (IPT) or 
multiple daily insulin injections (MDII). Diabetes is a chronic condition which requires essential 
life-long self-care behaviors. These behaviors promote positive outcomes such as healthy eating, 
physical activity, blood sugar monitoring, medication compliance, problem-solving skills, 
healthy coping skills and risk-reduction behaviors (Shrivastava, Shrivastava, & Ramasamy, 
2013). 
Problem Statement 
There is not enough data to establish a conclusive result that demonstrates the 
effectiveness of IPT in comparison to MDII in adult patients with type 1 diabetes. Many studies 
have suggested that IPT has improved glycemic control in adults with type 1 diabetes; however, 
its clinical impacts and other variables are not clear (Raskin, Bode, & Marks, 2003). Moreover, 
prior studies have been conducted mostly in pediatric populations or in type 2 diabetes 
populations (Nabhan et al., 2008). The desired outcome of this project is to generate the data, 
which will result in statistically significant values to determine the most effective treatment 
method for insulin delivery in this sample population. 
Purpose 
The purpose of the study was to compare the retrospective data of A1C and BMI of 
patients with type 1 diabetes after they transition from MDII to IPT. The goal was to evaluate the 
data for gap analysis to determine the most effective method of insulin delivery in a population 
with type 1 diabetes.  
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Hypotheses 
1. There will be an improvement in the A1C of adult patients with type 1 DM after 
transitioning from MDII to IPT.  
2. There will be an improvement in the BMI of adult patients with type 1 DM after 
transitioning from MDII to IPT. 
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CHAPTER 2: LITERATURE REVIEW 
 Diabetes is a chronic disease that requires continual monitoring and interventions. A 
review of the literature was undertaken to review study variables. Variables selected included 
IPT, MDII, hemoglobin A1c (A1C) and BMI. The A1C test is a blood test that gives an average 
blood glucose reading for the past three months. A1C below 7% is a target goal for diabetes 
management (ADA, 2016). Body mass index (BMI) in kilograms per meter squared, is a 
measure of body fat based on height and weight that applies to adult men and women. BMI is 
used to indicate if patient is overweight, obese, underweight or normal. A healthy BMI score is 
between 20 and 25 kg/m2 (ADA, 2016). 
Hermanides and colleagues (2011) conducted a multinational, multi-center randomized 
controlled clinical trial over 18-months to investigate the efficacy of sensor-augmented IPT vs. 
MDII therapy in patients with suboptimally controlled type 1 diabetes. The trial was completed 
by 43⁄44 (98%) patients in the sensor-augmented IPT group and 35⁄39 (90%) patients in the 
MDII group. The primary outcome measure, a change in A1C, was analyzed using an ANCOVA 
model. The differences in proportions of patients reaching A1C < 7% and experiencing a severe 
hypoglycemic episode was calculated using chi square analyses. Mean A1C at baseline and at 26 
weeks changed from 8.46% to 7.23% in the sensor-augmented IPT group and from 8.59% to 
8.46% in the MDII group. Mean difference in change in A1C after 26 weeks was 1.21% (P < 
0.001) in favor of the sensor-augmented IPT group. Although this study has few limitations, this 
study results showed reduction of A1C in group with insulin delivery by IPT.  
A prospective chart review by Boucher-Berry and colleagues (2016) was undertaken to 
discern whether the basal insulin dose or the bolus insulin dose added the most weight gain 
associated with insulin therapy. In this quantitative research study, researchers looked deeper 
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into IPT and the association with weight gain and BMI. Quantitative data such as A1C, height, 
weight, BMI, and tanner stage were collected from the one-year data from a total of 91 patients 
who were transitioned from basal-bolus regimen to IPT. Among them, 54 were female and 37 
were male patients between 2.3–17.8 years of age. Patients were divided into two groups based 
on changes in BMI: Group 1 (no change or decrease) and Group 2 (increase). The type of 
analysis was t-test and chi square (X 2) analyses. The two groups had similar total daily dose 
(TDD), (0.9 ± 0.2 vs.0.8 ± 0.2 U/kg/day), however Group 1 had a higher bolus: basal insulin 
ratio (1.8 ± 0.6 vs. 1.5 ± 0.6, p < 0.05). While Groups 1 and 2 had similar A1C values (7.7 ± 0.7 
vs. 7.70 ± 0.6 %; p = 0.79). 
Investigators concluded that even though the total insulin doses per kilogram of body 
weight remained same, the group that experienced the weight gain had a significantly higher 
basal insulin dosage than the other group. Findings suggests that the basal insulin dose is more of 
a contributor to the weight gain than the total insulin dose. The implication of this study was to 
reduce bolus and basal insulin doses during insulin to avoid excess weight gain (Boucher-Berry, 
et al., 2016).  
Alamoudi and colleague (2017) conducted a study to compare glucose profiles in patients 
with T1DM who were on IPT or MDII and decided to fast for Ramadan. Glucose data from self-
monitoring of blood glucose and continuous glucose monitoring were compared in the two 
groups. Researchers assessed glucose control by measuring serum fructosamine levels. 
Fructosamine level represents a measure of glycation of proteins in the plasma glucose. It 
reflects the average levels of blood glucose during the former 2-3 weeks (Danese, et al., 2015). 
A total of 156 patients participated in the study. Among them 61 were on IPT and 95 were on 
MDII.  
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The result of the study suggested that there was no difference in glycemic control in both 
groups as measured by fructosamine. Even though glucose variability was significantly better in 
the IPT group (SMBG; standard deviation [SD] 66.9 ± 15.3 vs. 76.9 ± 29.9, P = 0.02) (CGM; SD 
68.1 ± 19.6 vs. 78.7 ± 24.9, P = 0.04), there was no difference in glycemic control (Alamoudi, et 
al., 2017).  
Karges and colleague (2017) conducted a population-based cohort study between 446 
diabetes centers participating in the Diabetes Prospective Follow-up Initiative in Germany, 
Austria, and Luxembourg. Researchers identified patients with type 1 diabetes younger than 20 
years and diabetes duration of more than 1 year. Researchers also compared the insulin dose, 
A1C level and BMI in two groups.  
Among 30579 patients with mean age of 14.1 years, 14119 used IPT and 16460 used 
MDII. The IPT group had lower A1C levels than with MDII (8.04% vs 8.22%; difference, -0.18 
[95% CI, -0.22 to -0.13], P < .001). Even though total daily insulin doses were lower for IPT 
group compared to MDII group, there was no significant difference in BMI between both 
treatment regimens (Karges, et al., 2017). Investigators concluded that the children, adolescents, 
and young adults with type 1 diabetes who used IPT had improved clinical outcomes as 
compared to patients who used MDII. 
AbdulRasoul and colleague (2015) conducted a retrospective comparative study of IPT 
and MDII therapy in a large cohort of pediatric patients with type 1 diabetes in Kuwait. Data on 
326 patients who were started on IPT were retrospectively compared with those of 326 patients 
on MDII. They were matched for sex, age at diagnosis, duration of diagnosis, glycemic control, 
insulin requirement, and BMI. Data was collected for A1C, and insulin dose, at baseline and 
every three months. 
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The researchers found that the A1C decreased in both groups in the first year. However, 
A1C decrease was most significant in the IPT group compared to the MDII group in the first 
year and remained lower for IPT group throughout the study period. After the second year A1C 
levels in the MDII group gradually increased again to values higher than those measured at 
baseline (8.9±1.7 at baseline vs. 9.0 ± 1.2 in the fifth year, p<0.001). The difference in the A1C 
values at baseline and in the fifth year in the IPT and MDII group were 8.9±1.4 and 8.3±1.2 vs. 
8.8±1.4 and 9.0±1.6, respectively; p<0.05). BMI increased significantly for both groups at the 
end of the fifth year. There was no difference in the rate of diabetic ketoacidosis in either group. 
The IPT group had more severe hypoglycemic episodes at baseline but improved overtime. 
Ziegler and colleagues (2013) conducted a prospective, randomized, controlled, 
multinational study to evaluate the impact of using an insulin bolus advisor embedded in a blood 
glucose meter on glycemic control and treatment satisfaction in patients using MDII therapy. A 
total of 218 MDII-treated patients with poorly controlled diabetes (n=202 with type 1 diabetes, 
n=16 with type 2 diabetes) who were 18 years of age or older, were enrolled in a 26-week study.  
Participants had mean baseline A1C of 8.9% (SD, 1.2), and mean BMI of 26.5 kg/m2 (SD, 4.2). 
The study was designed to have 90% power to detect a mean difference of 0.5% change 
in A1C levels between two groups from baseline to study end in favor of the experimental group. 
This was determined using a one-sided, two-sample t test (α = 0.05) assuming a common SD of 
0.9% for the intention-to-treat population. Pearson correlation coefficients were computed for the 
A1C values and all other variables of interest. A total of 193 patients (Control n = 93; 
Experimental n = 100) completed the study. Significantly more experimental patients achieved 
>0.5% A1C reduction (56.0% vs. 34.4%; P < 0.01). A potential limitation of the study design 
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was both groups had received intensified diabetes care, which may explain why significant 
improvements were seen in both study groups (Ziegler et al., 2013). 
In this qualitative research study by Ferrari, Mcilwain, and Ambler (2016) children’s 
experience of different insulin regimens were studied. In this study, interviews with 17 children 
at two time points were analyzed; once on MDII, and again 4 months later after some subjects 
started IPT. Insulin pump therapy allowed children to listen to and trust their bodily cues rather 
than override cues. At the follow-up interview, eight children had transitioned to using insulin 
pump therapy for at least 3.5 months, and the remaining nine children were still using MDII. The 
conclusion of this study is that the children felt the insulin pump increased their flexibility in diet 
(Ferrari, Mcilwain, and Ambler, 2016). 
The study done by Wilkinson and his colleagues (2010) suggested that even though the 
use of insulin pump therapy increased, the patients with type 1 diabetes continued to have 
suboptimal control of diabetes (Wilkinson, et al., 2010). Researchers have concluded IPT can be 
an effective therapy for both children and adolescents, however just wearing the IPT are not 
sufficient to achieve the glycemic goal. Investigators found that it was important for patients to 
engage in self-care behaviors to achieve glycemic goal (Wilkinson, et al., 2010).  
Aronson and colleagues (2016) compared the efficacy of IPT and MDII in patients with 
type 2 diabetes. A total of 331 patients with A1C levels ≥8.0% and ≤12% were randomized to 
IPT or continued MDII for 6 months (randomization phase). During a 6-month continuation 
phase (CP), the MDII group was also subsequently switched to IPT. The researchers looked at 
the between-group difference in change in mean A1C from baseline to the end of the 
randomization phase (Aronson, et al., 2016).  
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The mean A1C at baseline was 9% in both groups. At the end of the randomization 
phase, the reduction in A1C was significantly greater with IPT than with MDII (−1.1±1.2% vs 
−0.4±1.1%; p<0.001). The IPT group maintained this improvement to 12 months. The MDII 
group, which was switched to IPT also showed a 0.8% reduction in A1C. The final A1C level 
was same in both groups. There were no differences in BMI or ketoacidosis between groups. 
Researchers concluded that IPT had a durable effect on glycemic control in uncontrolled type 2 
diabetes patients (Aronson, et al., 2016). 
Ackermann and colleagues (2017) conducted a study to evaluate blood glucose control 
for patients with diabetes who transitioned from MDII to IPT. The design of the study was pre-
post with propensity-matched comparison. The study participants had insulin-requiring diabetes 
and were commercially insured US adults, aged 18-64 years. They transitioned from MDII to 
IPT between July 1, 2009, and June 30, 2012 (IPT initiators = 2539), or who continued using 
MDII (n = 2539). Mean A1C, healthcare encounters for hypoglycemia, and direct medical 
expenditures were collected from the medical claims and laboratory results files obtained from a 
large US-wide healthcare payer.  
To compare A1C and healthcare expenditures for 3 years following the switch to IPT, the 
researchers had utilized difference-in-differences regression models (Ackermann, et al., 2017). 
Researchers found that IPT initiators had lower mean A1C concentration by 0.46% in year 2 (P = 
.0003) and by 0.32% in year 3 (P = .047). IPT users also had a higher rate of hypoglycemia 
episodes in year 1 (P = .002). However over 3 years, mean per-person total healthcare 
expenditures were $20,565 more/per-person for IPT users compared with matched MDII 
patients. Researchers concluded that transitioning from MDII to IPT was related with some 
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improvements in A1C but more hypoglycemia encounters and increased healthcare expenditures, 
for adults with insulin-requiring diabetes (Ackermann, et al., 2017). 
Summary of Literature Reviews 
The conclusion from the literature review was that the majority of the studies suggested 
use of IPT when compared to MDII showed better A1C in patient with insulin requiring diabetes 
(AbdulRasoul, et al., 2015; Aronson, et al., 2016; Ackermann, et al., 2017; Hermanides et al., 
2011; Karges, et al., 2017). Result of other studies suggested use of IPT when compared to MDII 
showed no statistically significant difference in A1C (Alamoudi, et al., 2017 and Boucher-Berry, 
et al., 2016).  
Lecture review revealed that even though total daily insulin doses were lower for IPT 
group compared to MDII group, there was no significant difference in BMI between both 
treatment regimens (AbdulRasoul, et al., 2015 and Karges, et al., 2017). Other studies suggested 
BMI increased significantly for both MDII and IPT groups in comparison to their baseline BMI 
but there was no difference in BMI between two treatment regimens (AbdulRasoul, et al., 2015; 
Boucher-Berry, et al., 2016; and Karges, et al., 2017). In a conclusion there was no difference in 
BMI between MDII and IPT group.  
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CHAPTER 3: METHODOLOGY 
Study Design 
The design of this research study was a retrospective cross sectional study via chart 
review. A total of 58 patients with type 1 diabetes seen in 2017 at a Sacramento Endocrinology 
group who transitioned from MDII to IPT were selected. Patient’s pre-insulin pump data such as 
A1C and BMI was compared to post-insulin pump therapy over 3-time points. The independent 
variable in this study was pre-IPT and post-IPT. The dependent variables were A1C and BMI. 
Research Questions 
1. (a) Is there a difference in the A1C of adult patients with type 1 DM after transitioning 
from MDII to IPT? 
(b) Is there a difference in the BMI of adult patients with type 1 DM after transitioning 
from MDII to IPT? 
2. (a) Is there a relationship between A1C of patients with type 1 DM after transitioning 
from MDII to IPT? 
(b) Is there a relationship between BMI of adult patients with type 1 DM after 
transitioning from MDII to IPT? 
Method 
The method of the study was a quantitative approach, retrospective, cross sectional, non-
experimental, and descriptive design. The data were collected by retrospective chart review. 
Patients were identified by utilizing the electronic database. Patients were selected for the study 
by inclusion criteria. Patients who met the exclusion criteria were removed from the study. The 
total population who met all criteria composed the population of interest.   
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Population and Sample Selection 
Demographic data including patient age and gender was collected. A convenience sample 
was selected by inclusion and exclusion criteria. The inclusion criteria included adult patients, 
18-85 years of age, with type 1 DM, who used MDII for at least one year before transitioning to 
IPT. Patients needed to be on IPT for at least one year. Exclusion criteria included patients who 
have been admitted more than two times in a year due to the severe disease complication 
diabetes ketoacidosis (DKA) and non-adherence defined by three consecutive cancellations of 
appointments, and patients with type 2 diabetes. 
Settings and Data Collection 
The study took place in one of the clinics in the endocrinology department of a large 
Northern California medical group. The department cares for a total of 273 adult patients with 
type 1 diabetes. Electronic data collection technology was utilized to collect the information of 
the patient’s age, gender, BMI, and A1C. Data were collected before and after patient transition 
to IPT at 3, 6, and 12 months post-IPT. Timeframe of data collection for each patient using IPT 
was differ, as each patient had started the IPT at different time.  
Protection of Human Subjects 
To assure protection of patient confidentiality and human rights, the Institutional Review 
Board (IRB) at Dignity Health Medical Foundation and the IRB at Fresno State University 
approved this project. Subjects were de-identified by an information technology specialist who 
randomly assigned an identification number before data collection took place. Only data 
variables under study were collected from patient records and placed on electronic spreadsheets. 
Spreadsheets were saved within a locked and coded computer. The researcher was the only 
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individual who conducted the chart review to gather the data from the patients’ electronic 
medical records. 
Theoretical Framework 
Orem’s self-care deficit nursing theory was utilized to guide this research. The theory of 
self-care was directly applicable to the patient with diabetes. Self-care deficit theory has been 
tested, researched, and published in the literature (Orem et al., 2003). Orem believed the self-
care action the maintenance of human functioning such as the continuance of life, health, and 
well-being were possible. Even though, these actions have been routine and spontaneous, they 
were driven by the functional needs of human beings (Orem et al., 2003).  
The concept of the self-care theory explains that every individual thrived and recovered 
faster by participating in their self-care as much as possible. Self-care theory has been relevant to 
diabetes self-management and has been directly applicable to diabetes care. Self-management 
skills are essential for the quality of life for patients with diabetes (Mensing & Cornell, 2014) in 
the context of both IPT and MDII. Designing an effective intervention to help patients with 
diabetes reach A1C and BMI goals was the focus of this research project.  
Data Analysis 
The data were analyzed using the IBM® SPSS (Statistical Package for the Social 
Sciences). Descriptive statistics (means, standard deviations, frequencies) for all study variables 
were obtained. Bivariate correlations between A1C and BMI measurements were conducted. The 
Pearson correlation coefficient test was conducted to analyze the relationship of A1C and BMI. 
Two repeated measures ANOVAs were conducted within subjects for both A1C and BMI. 
Repeated measure ANOVA was utilized to examine differences within subjects after starting 
IPT. Level of significance was established at p = 0.05.  
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CHAPTER 4: RESULTS 
A total of 114 patients’ charts were reviewed and 58 were selected for the study based on 
inclusion and exclusion criteria. The mean age of the sample was 46 (minimum age 21, 
maximum age 80). Over half of the subjects were female (51.7% female, 48.3% male). Bivariate 
correlations reveled that there were a significant relationships between all four A1C measures. 
There were significant relationships between all four BMI measures. However, there were no 
significant relationships between any A1C and BMI measurements (see Table 1). 
Table 1 
 
Pearson Correlations Between A1C and BMI Measurement Overtime 
 
Note. ** p<.01 
 
 
Variables 1 2 3 4 5 6 7 
1. A1C Baseline - 
      
2. A1C 3 Months  .73** -      
3. A1C 3-6 Months  .80** .76** -     
4. A1C 6-12 Months  .74** .68** .90** -    
5. BMI Baseline -.20  -.03 -.07 -.08 -   
6. BMI 3 Months -.11  -.04  .02 -.01 .98** -  
7. BMI 3-6 Months -.09  -.07  .04 -.01 .97** .98** - 
8. BMI 6-12 Months -.10   .09  .03 -.02 .96** .98** .99** 
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Baseline mean A1C was 8.31% and 3 months, 6 months and 12 months post-pump A1C were 
7.75%, 7.86% and 7.9% respectively. A statistically significant difference was found across the 
four time period measurements of A1C in adult patients with type 1 DM after transitioning from 
MDII to IPT over time F (2.32, 130.13)= 6.82, p <.01. Post hoc revealed that there was a 
statistically significant difference between the base line A1C and post-IPT A1C. There was a 
statistically significant difference between baseline A1C to 3 months (p <.01), and 3-6 months (p 
<.01) post-IPT A1C. There was no significant difference between mean baselines A1C to 12 
months post-IPT A1C level. Mean A1C had decreased from baseline to 3 months and 3-6 months 
post-IPT but stayed relatively stable after 12 months (see Table 2). Figure 1 shows the line graph 
of these measurements.  
Table 2 
 
Repeated Measures ANOVA Results for A1C and BMI 
Variables M SD Df F p Ƞ2 
A1C   2.32,130.13 6.82 .001 .11 
Baseline 8.31 1.73     
3 Months 7.75 1.03     
3-6 Months 7.90 1.32     
6-12 Months 7.90 1.32     
BMI   2.02,113.50 3.70 .03 .06 
Baseline 27.95 5.99     
BMI 3 Months 28.42 5.70     
BMI 3-6 Months 28.41 5.78     
BMI 6-12 Months 28.34 5.78     
16 
 
 
  
 
Figure 1. Line graph showing A1C measurement over the four-time periods. 
 
There was a significant difference across the four time period measurement of BMI in adult 
patients with type 1 DM after transitioning from MDII to IPT over time F (2.02, 113.50)= 3.70, 
p<.05. Baseline mean BMI was 27.95 kg/m2 and 3 months, 6 months and 12 months post-IPT 
BMI were 28.42 kg/m2, 28.41 kg/m2, and 28.38 kg/m2 respectively. Post hoc revealed that there 
was a statistically significant (p< .04) difference between baseline BMI and 3 months post-IPT 
BMI. BMI increased from baseline to 3 months post-IPT but stayed relatively stable after 3-6 
months and 12 months (see Table 2). Figure 2 shows the line graph of these measurements.  
17 
 
 
 
Figure 2. Line graph showing BMI measurement over the four-time periods.  
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CHAPTER 5: DISCUSSION  
The first hypothesis stated there will be an improvement in the A1C of adult patients with 
type 1 diabetes after transitioning from MDII to IPT. This study showed an improvement in the 
A1C of adult patients with type 1 diabetes after transitioning from MDII to IPT. There was a 
significant difference across the four time periods in the measurement of A1C in adult patients 
with type 1 diabetes after transitioning from MDII to IPT. Post hoc analysis was done to find out 
where the actual difference was observed in A1C in those four time period measurements. It was 
found that the actual difference was observed between the baseline A1C to 3 months post-IPT 
A1C and baseline A1C to 3-6 months post-IPT A1C. Mean A1C decreased significantly from 
baseline (M=8.31%, SD= 1.73) to 3 months (M=7.75%, SD= 0.14) and 3-6 months post-pump 
period (M=7.86%, SD= 0.18). There was no difference in mean A1C from baseline to 12 months 
post-IPT.  Findings revealed results similar to those found in previous literature review 
(Alamoudi, et al., 2017 and Boucher-Berry, et al., 2016; Wilkinson, et al., 2010). 
The second hypothesis was that there will be an improvement in the BMI of adult 
patients with type 1 diabetes after transitioning from MDII to IPT. This study did not support the 
hypothesis as the results did not show any improvement in the BMI of adult patients with type 1 
diabetes after transitioning from MDII to IPT. There was a significant difference across the four 
time period measurements of BMI after transitioning from MDII to IPT. Post hoc analysis was 
done to find out where the actual difference was observed in BMI in those four time period 
measurements. Mean BMI increased significantly from baseline (M=27.9502 kg/m2, SD= 6.0) to 
3 months post-IPT (M=28.4175 kg/m2, SD= 5.7). However, there was no difference in mean 
BMI from baseline to 3-6 months and baseline to 12 months post-IPT. Findings revealed results 
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similar to those found in previous literature review (AbdulRasoul, et al., 2015 & Karges, et al., 
2017).  
There was not any relationship between A1C and BMI in patients with type 1 diabetes. 
There were significant positive relationships between all four times period measurements of A1C 
in adult patients with type 1 diabetes. There were also significant positive relationships between 
all four times period measurements of BMI in adult patients with type 1 diabetes.  
The conclusion was that the use of IPT when compared to MDII demonstrated a 
statistically significant improvement in A1C for 3 months and 3-6 months post pump but the 
improvement did not sustain overtime. Some reviewed studies suggested use of IPT when 
compared to MDII showed better A1C (AbdulRasoul, et al., 2015; Aronson, et al., 2016; 
Ackermann, et al., 2017; Hermanides et al., 2011; Karges, et al., 2017) but other studies 
suggested no statistically significant difference in A1C between two groups(Alamoudi, et al., 
2017 and Boucher-Berry, et al., 2016). Also, BMI increased significantly from baseline to 3 
months post pump and remained the same throughout the period. There was no difference 
between baselines BMI to 12 months post-IPT BMI. Findings revealed results similar to those 
found in previous research investigations reported in the literature review (AbdulRasoul, et al., 
2015; Boucher-Berry, et al., 2016; & Karges, et al., 2017). 
Most of the times, among the sample population, improved A1C levels were observed 
after patients transitioned to IPT from the MDII. Therefore, A1C was expected to remain lower 
after transitioning to IPT. However, that was just an assumption as there was no prior study done 
with this patient population to measure the difference in A1C after patients transitioned to IPT 
from MDII. In this study patient had lower A1C for 3 months and 3-6 months after transiting to 
IPT which was expected finding but A1C not remaining lower was unexpected. It is possible that 
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in the beginning of the transition from the MDII to IPT, patients might have been more active in 
managing their blood sugars after the initiation of new form of insulin delivery. It may also be 
due to dietary control or accurate carbohydrate counting while using the IPT. 
In this study, patients initially gained weight after transitioning from MDII to IPT but 
there was no difference between base line BMI to 12 months post-IPT BMI , which is consistent 
with the literature reviewed (Boucher-Berry, et al., 2016; AbdulRasoul, et al., 2015). It is 
possible that patients might have gained weight because they did not have much glycosuria due 
to better glycemic control. However it was expected that BMI will improve with IPT use because 
patients use less insulin while on IPT than MDII.  
Finally, hypoglycemia was not assessed due to inconsistent or lack of recorded data 
within the patient chart. One of the challenges of managing type 1 diabetes is the need to control 
hyperglycemia and hypoglycemia (Pavlicek, 2015). Findings regarding the relationship between 
A1C and hypoglycemia has been controversial. Some literature suggests that the IPT group had 
significantly lower rates of severe hypoglycemia compared to MDII (Karges, et al., 2017). 
However, other research studies suggest that the reduction in A1C could be related to frequent 
hypoglycemia as IPT group had more hypoglycemia than MDII (Ackermann, et al., 2017; 
Wainstein, et al., 2005). Moreover, many research studies did not find any difference in 
hypoglycemia rate between IPT and MDII (Hermanides, et al., 2011; Alamoudi, et al., 2017, 
Zigler, et al., 2013). Investigating the AIC with recorded incidence of hypoglycemia may also 
influence IPT results. 
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Limitations of the Project 
Selection. In this study patients were not randomly selected; one of the threats to internal validity 
is self-selection biases. Self-selection biases result in pre-existing differences between groups 
(Polit, & Beck, 2008). There is always a risk that the groups are nonequivalent, so the outcome 
may result from the initial differences rather than the effects of independent variables. However, 
convenience samples are often used in medical research.  
Non experimental design. Using a non-experimental design can limit control of other variables 
such as diet and exercise. Diet and exercise play an important role in glycemic control; therefore, 
it is important to incorporate data on diet and exercise. Diet and exercise regimen may vary 
between individuals and this was not controlled in the current study. Self-reported diet and 
exercise measures were considered, however, they do not have high validity.    
Maturation. Maturation in a research context means the processes that include physical growth, 
emotional maturity, fatigue, or disease burn out (Polit, & Beck, 2008). The length of the current 
study was 12 months, and there was a slight threat to internal validity related to maturity. The 
outcomes of the study may have been influenced by the amount of time a patient has been 
diagnosed with diabetes. For example, patients who have had diabetes for many years might 
have a different level of expertise with the self-management of their disease than those who are 
newly-diagnosed. The efficacy of IPT in young T1DM adults was worse than in older patients, 
which could be due to age-dependent behaviors, social environment, or both (Grzanka, et al., 
2012). On the other hand, patients with long histories of diabetes may suffer from disease burn 
out, which may result in low adherence to self-managing their disease.  
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Conclusion 
Managing diabetes is a challenge. Reaching target A1C levels and BMI goals can be used 
as standard measures, however good control of diabetes requires good A1C with no or minimal 
hypoglycemia rates. Therefore, it is crucial for clinicians to also monitor and record 
hypoglycemia rates along with A1C and BMI. 
In addition, IPT is not accessible to all populations. IPT is expensive and most insurance 
policies do not fully cover the insulin pump and supplies. Although this study supported IPT use, 
it also showed only a short-term reduction of AIC and BMI when initiating the pump. What has 
become clear is for this sample during the transition from MDII to IPT elevations of A1C did not 
occur.  
It is important for the clinician to consider the individual when planning a transition to 
IPT. Clinicians need to consider individual patient preferences about using IPT in patients with 
type 1 diabetes. It is also important to engage in self-care behavior to achieve glycemic goal. 
Better glycemic control and prevention of disease-related complications are the goals of diabetes 
management. Designing effective interventions to help patients with diabetes reach AIC and 
BMI goals are the focus of the diabetes management, whether or not it is reached by the IPT or 
MDII. 
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APPENDIX C: DEFINITION OF TERMINOLOGY 
 
HbA1C: HbA1C test is a blood test that reflects average blood glucose levels over the past 3 
months. The HbA1C test is also called the hemoglobin A1C, A1C, HbA1c, glycated hemoglobin, 
or glycohemoglobin test.  
BMI: Body mass index (BMI) in kilograms per meter squared, is a measure of body fat based on 
height and weight that applies to adult men and women. BMI is used to indicate if patient is 
overweight, obese, underweight or normal. A healthy BMI score is between 20 and 25 kg/m2. 
Hypoglycemia: Hypoglycemia, also known as low blood glucose is a condition characterized by 
abnormally low blood glucose (usually less than 70 mg/dl), which in extreme cases can lead to 
unconsciousness and death. 
Insulin Pump Therapy: is a continuous subcutaneous insulin infusion through a pump that 
delivers insulin continuously under the skin through a small plastic tube and cannula. Pumps are 
filled with rapid acting insulin to supply both background insulin and mealtime insulin. 
 
